Gene Transplant Market

Rising Cancer Cases Likely to Spur Growth of the Gene Transplant Market

The Gene Transplant Market is valued at USD 4.6 Bn in 2026 and is projected to reach USD 11.4 Bn,  growing at a CAGR of 14% by 2033.Since past few decades, advancements in genome engineering facilitated use of gene transplant in management and treatment of malignant diseases such as cancer. A foreign gene is introduced directly in the cancer cells and surrounding tissues, which prevents cancer cells from spreading and kill them eventually. This novel technique in treating cancer is expected to drive growth of the gene transplant market in the coming years. Moreover, higher prevalence of cancer worldwide is likely to influence adoption of gene transplant. According to International Agency for Research on Cancer (IARC) observations, by end of 2040, 30 million cancer cases are likely to be witnessed. As per analysis of the Global Cancer Observatory, in 2020, 19,292,789 cases were recorded, from which 9,958,133 fatalities were witnessed. Various gene transplant procedures such as anti-angiogenic therapy, suicide gene therapy, RNAi strategies and oncolytic virotherapy are being employed for the treatment of lung cancer, brain cancer, breast cancer, liver and colorectal cancer, skin cancer and pancreatic cancers. That said, rising cancer cases worldwide are expected to drive demand for gene transplant, in turn bolstering growth of the gene transplant market.

Risks Associated with Transplant Procedure Can Hinder Gene Transplant Market Growth

Gene transplant market continues to remain impacted by potential adverse effects associated with the therapy. Gene transplant process includes presence of a vital carrier called as vector, which is essentially a virus type that recognizes cells and carries the genetic material in genes of those cells. The original diseased genes are removed and are replaced by other genes that stop the disease. However, this process is accompanied by major risks such as wrong cell targeting, unwanted reactions in the immune system, possibility of infections and tumour formation. This can cause healthy cells to get damaged, inflammation in the immune system and organ failures which can critically impact patients’ well being. This aspect continues to challenge the procedure, in turn embossing a negative impact on the growth of the gene transplant market.

Gene Transplant Market Growth to Remain Influenced by Favourable Support from Regulatory Bodies

Initiatives by regulatory authorities to enhance effectiveness of gene therapy procedures for treatment of rare diseases is likely of favour growth of the gene transplant market. Understanding the challenges faced during gene transplant procedures, regulatory authorities such as National Institutes of Health (NIH) and FDA are overseeing trials to ensure patient safety. Moreover, NIH, FDA, 5 non-profit organizations and 10 pharmaceutical giants joined forces in 2021 to increase the effectiveness of gene transplant procedures and accelerate their development to serve millions of individuals suffering from rare diseases. Development of BGTC (Bespoke Gene Therapy Consortium) was initiated by NIH to streamline and optimize gene transplant procedure. BGTC will also explore different methods and processes for gaining FDA approvals of effective and safe gene therapies, which includes development of standardized approaches towards preclinical testing. NIH along with private partners will continue to support BJTC by contributing US$76 million for five years. Moreover, recent FDA approvals are also expected to fuel growth of the gene transplant market. For instance, first of its kind cell-based therapy, particularly for adults suffering from multiple myeloma was approved by FDA in 2021.

North America Gene Transplant Market to Showcase a Stable Growth Pace in the Coming Years

The gene transplant market in North America is expected to witness stable growth pace in the coming years on the back of favourable infrastructure and regulations. For instance, in the United States, the Department of Health and Human Services (DHHS) and OHRP (Office for Human Research Protections) is appointed to monitor clinical trials apropos to gene transplant. Moreover, according to CDC (), cancer cases among adults will increase by 49% by end of 2050 to touch 2,286,300 from a count of 1,534,500 in 2015. Also, companies in the region are entering into strategic collaborations to increase their share. For example, Sangamo Therapeutics and Biogen entered into a partnership reflecting a US$ 2.7 billion deal in 2020, particularly to focus on gene transplant candidates of Sangamo – the ST-502 for Parkinson’s and ST-501 for Alzheimer’s disease. Such developments are likely to influence the growth of the gene transplant market in the developed economies of North America in the years to follow.

Few of the key players in the gene transplant market are 

• Bayer AG
• Novartis AG
• CSL Behring LLC
• Charles River Laboratories International Inc.
• BioMarin Pharmaceutical Inc.
• Sarepta Therapeutics Inc.
• Ultragenyx Pharmaceutical Inc.
• CRISPR Therapeutics AG
• Beam Therapeutics Inc.
• Rocket Pharmaceuticals Inc.
• Voyager Therapeutics Inc.
• Sangamo Therapeutics Inc.
• Editas Medicine Inc.
• Bluebird Bio Inc.
• Orchard Therapeutics plc

By Product:

• Instruments
• Consumables
• Reagents
• Kits
• Assays

By Mode:

• Viral Vector
• Non-viral Vector

By Method:

• Ex Vivo
• In Vivo
• In Vitro

By Application:

• Research
• Therapeutic
• Other

By End User:

• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Other

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa